Literature DB >> 17158941

Evaluation of accessory gene regulator (agr) group and function in the proclivity towards vancomycin intermediate resistance in Staphylococcus aureus.

Brian T Tsuji1, Michael J Rybak, Kerry L Lau, George Sakoulas.   

Abstract

Simulated therapeutic vancomycin exposures were evaluated against agr wild-type and knockout Staphylococcus aureus groups I, II, III, and IV using an in vitro pharmacodynamic model. All agr groups developed intermediate resistance to vancomycin after subtherapeutic exposure. The free unbound fraction of the area under the concentration-time curve (fAUC/MIC) required to suppress resistance was fourfold higher (P < 0.001) in agr dysfunctional strains (112 to 169) than that in parent wild-type strains (28).

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17158941      PMCID： PMC1803123          DOI： 10.1128/AAC.00671-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  16 in total

1.  Key determinants of receptor activation in the agr autoinducing peptides of Staphylococcus aureus.

Authors:  Gholson J Lyon; Jesse S Wright; Tom W Muir; Richard P Novick
Journal:  Biochemistry       Date:  2002-08-06       Impact factor: 3.162

Review 2.  Autoinduction and signal transduction in the regulation of staphylococcal virulence.

Authors:  Richard P Novick
Journal:  Mol Microbiol       Date:  2003-06       Impact factor: 3.501

3.  Bacterial interference caused by autoinducing peptide variants.

Authors:  G Ji; R Beavis; R P Novick
Journal:  Science       Date:  1997-06-27       Impact factor: 47.728

4.  Staphylococcus aureus accessory gene regulator (agr) group II: is there a relationship to the development of intermediate-level glycopeptide resistance?

Authors:  George Sakoulas; George M Eliopoulos; Robert C Moellering; Richard P Novick; Lata Venkataraman; Christine Wennersten; Paola C DeGirolami; Mitchell J Schwaber; Howard S Gold
Journal:  J Infect Dis       Date:  2003-03-06       Impact factor: 5.226

5.  Accessory gene regulator (agr) locus in geographically diverse Staphylococcus aureus isolates with reduced susceptibility to vancomycin.

Authors:  George Sakoulas; George M Eliopoulos; Robert C Moellering; Christine Wennersten; Lata Venkataraman; Richard P Novick; Howard S Gold
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

6.  Reduced susceptibility of Staphylococcus aureus to vancomycin and platelet microbicidal protein correlates with defective autolysis and loss of accessory gene regulator (agr) function.

Authors:  George Sakoulas; George M Eliopoulos; Vance G Fowler; Robert C Moellering; Richard P Novick; Natalie Lucindo; Michael R Yeaman; Arnold S Bayer
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

7.  In vitro activities of quinupristin-dalfopristin and cefepime, alone and in combination with various antimicrobials, against multidrug-resistant staphylococci and enterococci in an in vitro pharmacodynamic model.

Authors:  George P Allen; Raymond Cha; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

8.  Endocarditis caused by Staphylococcus aureus with reduced susceptibility to vancomycin.

Authors:  Christopher W Woods; Allen C Cheng; Vance G Fowler; Mary Moorefield; Joyce Frederick; George Sakoulas; Venkata G Meka; Fred C Tenover; Peter Zwadyk; Kenneth H Wilson
Journal:  Clin Infect Dis       Date:  2004-04-05       Impact factor: 9.079

9.  Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy.

Authors:  Pamela A Moise-Broder; George Sakoulas; George M Eliopoulos; Jerome J Schentag; Alan Forrest; Robert C Moellering
Journal:  Clin Infect Dis       Date:  2004-05-21       Impact factor: 9.079

10.  Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia.

Authors:  George Sakoulas; Pamela A Moise-Broder; Jerome Schentag; Alan Forrest; Robert C Moellering; George M Eliopoulos
Journal:  J Clin Microbiol       Date:  2004-06       Impact factor: 5.948
View more
  35 in total

1.  Preferential emergence of reduced vancomycin susceptibility in health care-associated methicillin-resistant Staphylococcus aureus isolates during continuous-infusion vancomycin therapy in an in vitro dynamic model.

Authors:  Sheryl Zelenitsky; Noha Alkurdi; Zhanni Weber; Robert Ariano; George Zhanel
Journal:  Antimicrob Agents Chemother       Date:  2011-04-18       Impact factor: 5.191

2.  Predictors of agr dysfunction in methicillin-resistant Staphylococcus aureus (MRSA) isolates among patients with MRSA bloodstream infections.

Authors:  Jill M Butterfield; Brian T Tsuji; Jack Brown; Elizabeth Dodds Ashley; Dwight Hardy; Kristen Brown; Alan Forrest; Thomas P Lodise
Journal:  Antimicrob Agents Chemother       Date:  2011-09-19       Impact factor: 5.191

3.  Studies on the mechanism of telavancin decreased susceptibility in a laboratory-derived mutant.

Authors:  Yang Song; Christopher S Lunde; Bret M Benton; Brian J Wilkinson
Journal:  Microb Drug Resist       Date:  2013-04-03       Impact factor: 3.431

4.  Polymyxin B in combination with doripenem against heteroresistant Acinetobacter baumannii: pharmacodynamics of new dosing strategies.

Authors:  Gauri G Rao; Neang S Ly; Jürgen B Bulitta; Rachel L Soon; Marie D San Roman; Patricia N Holden; Cornelia B Landersdorfer; Roger L Nation; Jian Li; Alan Forrest; Brian T Tsuji
Journal:  J Antimicrob Chemother       Date:  2016-08-03       Impact factor: 5.790

5.  Impact of Staphylococcus aureus accessory gene regulator (agr) system on linezolid efficacy by profiling pharmacodynamics and RNAIII expression.

Authors:  Rachel L Soon; Justin R Lenhard; Irene Reilly; Tanya Brown; Alan Forrest; Brian T Tsuji
Journal:  J Antibiot (Tokyo)       Date:  2016-06-08       Impact factor: 2.649

6.  Risk Factors for Non-Therapeutic Initial Steady-State Vancomycin Trough Concentrations in Children and Adolescents Receiving High Empiric Doses of Intravenous Vancomycin.

Authors:  Whitney R Buckel; Shahira Ghobrial; Pranita D Tamma; Aaron M Milstone; Yuan Zhao; Alice J Hsu
Journal:  Paediatr Drugs       Date:  2017-02       Impact factor: 3.022

7.  Factors influencing time to vancomycin-induced clearance of nonendocarditis methicillin-resistant Staphylococcus aureus bacteremia: role of platelet microbicidal protein killing and agr genotypes.

Authors:  Pamela A Moise; Alan Forrest; Arnold S Bayer; Yan Q Xiong; Michael R Yeaman; George Sakoulas
Journal:  J Infect Dis       Date:  2010-01-15       Impact factor: 5.226

8.  Accessory gene regulator (agr) dysfunction in Staphylococcus aureus bloodstream isolates from South Korean patients.

Authors:  Yong Pil Chong; Eun Sil Kim; Su-Jin Park; Ki-Ho Park; Tark Kim; Mi-Na Kim; Sung-Han Kim; Sang-Oh Lee; Sang-Ho Choi; Jun Hee Woo; Jin-Yong Jeong; Yang Soo Kim
Journal:  Antimicrob Agents Chemother       Date:  2012-12-17       Impact factor: 5.191

Review 9.  Use of vancomycin pharmacokinetic-pharmacodynamic properties in the treatment of MRSA infections.

Authors:  Christopher Giuliano; Christopher Giulano; Krystal K Haase; Ronald Hall
Journal:  Expert Rev Anti Infect Ther       Date:  2010-01       Impact factor: 5.091

10.  agr Dysfunction and persistent methicillin-resistant Staphylococcus aureus bacteremia in patients with removed eradicable foci.

Authors:  S-Y Park; Y P Chong; H J Park; K-H Park; S M Moon; J-Y Jeong; M-N Kim; S-H Kim; S-O Lee; S-H Choi; J H Woo; Y S Kim
Journal:  Infection       Date:  2012-10-12       Impact factor: 3.553
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.